Roivant Sciences Shares Jump on Mosliciguat Trial Success

The clinical trial demonstrated a statistically significant, placebo-adjusted reduction in pulmonary vascular resistance for those treated with mosliciguat. Beyond the primary endpoint, the company confirmed that all secondary goals of the study were also achieved. This drug targets pulmonary hypertension associated with interstitial lung disease, a condition notorious for its high mortality rate and lack of viable treatment options.

Marc Humbert, director of the French National Reference Center for Pulmonary Hypertension, noted that the disease remains exceptionally difficult to manage due to its heterogeneous nature and the poor tolerance many patients show toward existing therapies. He characterized the new data as a major advancement, suggesting that mosliciguat could finally bridge a persistent gap in care for a vulnerable population.